RheumShorts: Methotrexate, Basiliximab, and Norwegian Lyme MedPage Today Increases in the soluble interleukin-2 receptor (CD25) have been identified in patients with autoimmune diseases such as systemic sclerosis, and a recent open-label study found benefits for basiliximab among patients with progressive systemic sclerosis. |
